SCHEMBL5113769

SCHEMBL5113769

CC(C)(C)OC(=O)NCCNC1CCCCC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.73
GAA P10253 2/20 0.50
TDP1 Q9NUW8 1/20 0.46
BTK Q06187 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
CTSS P25774 1/20 0.41
CTSK P43235 1/20 0.41
CXCR4 P61073 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OGFRL1 Q5TC84 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5416045 0.98 EPHX1 (0.70) EPHX1GAATDP1BTKMEN1
SCHEMBL19263939 0.95 EPHX1 (0.66) EPHX1GAATDP1BTKMEN1
SCHEMBL5619433 0.92 EPHX1 (0.60) EPHX1GAATDP1BTKMEN1
SCHEMBL24435431 0.91 EPHX1 (0.65) EPHX1GAATDP1MEN1KMT2A
SCHEMBL12894206 0.91 EPHX1 (0.65) EPHX1GAATDP1MEN1KMT2A
SCHEMBL18257482 0.89 EPHX1 (0.60) EPHX1GAATDP1BTKMEN1
SCHEMBL13627401 0.89 EPHX1 (0.62) EPHX1GAATDP1BTKMEN1
SCHEMBL26043679 0.89 EPHX1 (0.62) EPHX1GAATDP1BTKMEN1
SCHEMBL26158775 0.88 EPHX1 (0.62) EPHX1GAATDP1BTKMEN1
SCHEMBL22096232 0.88 EPHX1 (0.59) EPHX1GAATDP1BTKMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142543-B2 Antidepressant compound and preparation method and application thereof SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2021-10-12 US disclosed
US-20200385418-A1 ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) 2020-12-10 US disclosed
EP-3564253-A1 ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2019-11-06 EP disclosed
US-7414067-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2008-08-19 US disclosed
EP-1610776-A4 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO INC (US) 2007-03-28 EP disclosed
US-20060069256-A1 Ophthalmic compositions for treating ocular hypertension EVOTEC OAI (GB) 2006-03-30 US disclosed
EP-1610776-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co. Inc. (US) 2006-01-04 EP disclosed
WO-2004087051-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069256-A1 Ophthalmic compositions for treating ocular hypertension KCNN1, KCNN3, KCNN2 EPHX1 1491/4885GAA 2150/4885TDP1 2978/4885
US-11142543-B2 Antidepressant compound and preparation method and application thereof TPH1, BDNF, CRH EPHX1 1551/4885GAA 1014/4885TDP1 2801/4885
US-20200385418-A1 ANTIDEPRESSANT COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF TPH1, BDNF, CRH EPHX1 1551/4885GAA 1014/4885TDP1 2801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.